# Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers

> **NCT02271334** · PHASE2 · COMPLETED · sponsor: **Amphastar Pharmaceuticals, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** A006 DPI
- **DRUG:** A006 DPI
- **DRUG:** Proventil® MDI
- **DRUG:** Proventil® MDI

## Key facts

- **NCT ID:** NCT02271334
- **Lead sponsor:** Amphastar Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2014-10
- **Final completion:** 2015-03
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02271334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02271334, "Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02271334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*